Latest news with #SharonBarr
NDTV
13-06-2025
- Business
- NDTV
AstraZeneca Inks China AI Research Deal For Chronic Diseases
British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC Pharmaceuticals worth up to $5.3 billion to tackle chronic diseases. AstraZeneca, which has a pre-existing collaboration with CSPC, announced earlier this year plans to invest $2.5 billion in China. "This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally," said AstraZeneca executive vice president Sharon Barr. AstraZeneca aims to develop a research and development centre of up to 1,700 people in the country. CSPC will carry out the research in Shijiazhuang, using "their AI-driven, dual-engine efficient drug discovery platform", the firm said. AstraZeneca said the agreement will see CSPC receive an upfront payment of $110 million, plus up to $1.62 billion in "potential development milestone payments" and up to a further $3.6 billion in sales milestone payments, along with annual sales-based royalties. The multinational will also be able to exercise options for exclusive licences to develop and commercialise worldwide candidates identified under the deal.
Yahoo
13-06-2025
- Business
- Yahoo
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Economic Times
13-06-2025
- Business
- Economic Times
AstraZeneca signs AI research deal with China's CSPC for chronic diseases
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City. "This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally," AstraZeneca executive Sharon Barr said in a statement. Friday's agreement follows AstraZeneca's announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with Immunai, and Tempus AI. AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion for reaching development milestones and $3.6 billion linked to sales-related milestones, the groups said in separate statements. They signed a licensing deal last October in which AstraZeneca agreed to pay up to $1.92 billion to CSPC to develop a candidate which would boost its cardiovascular pipeline. AstraZeneca and CSPC both have wide-ranging pipeline portfolios, including cancer treatments and those targeting cardiovascular diseases. However, about 80% of CSPC's total revenue comes from its finished drug segment, according Morningstar analysts. The Chinese group said last month it was in negotiations with third parties on new licensing and collaboration. Friday's agreement also gives AstraZeneca the rights to exercise options for exclusive licenses for candidates identified as part of the collaboration.
Business Recorder
13-06-2025
- Business
- Business Recorder
AstraZeneca signs AI research deal with China's CSPC for chronic diseases
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City. 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally,' AstraZeneca executive Sharon Barr said in a statement. Friday's agreement follows AstraZeneca's announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with Immunai, and Tempus AI. AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion for reaching development milestones and $3.6 billion linked to sales-related milestones, the groups said in separate statements. They signed a licensing deal last October in which AstraZeneca agreed to pay up to $1.92 billion to CSPC to develop a candidate which would boost its cardiovascular pipeline. AstraZeneca and CSPC both have wide-ranging pipeline portfolios, including cancer treatments and those targeting cardiovascular diseases. However, about 80% of CSPC's total revenue comes from its finished drug segment, according Morningstar analysts. The Chinese group said last month it was in negotiations with third parties on new licensing and collaboration. Friday's agreement also gives AstraZeneca the rights to exercise options for exclusive licenses for candidates identified as part of the collaboration.
Yahoo
20-05-2025
- Business
- Yahoo
AstraZeneca PLC (AZN) Trial: Airsupra Cuts Severe Asthma Risk by 47%
AstraZeneca PLC (NASDAQ:AZN), a pharmaceutical and biotech firm based in Cambridge, UK, reported positive results from its Phase 3b Batura trial. The study found that Airsupra, its dual-action asthma rescue inhaler, led to meaningful improvements in patients with mild asthma compared to albuterol alone. AIRSUPRA is the only FDA-approved rescue inhaler designed to both relieve asthma symptoms and help prevent asthma attacks. It is a pressurized metered-dose inhaler that combines albuterol and budesonide. The FDA approved the inhaler in January 2023 for use as needed to manage or prevent asthma symptoms and reduce the risk of sudden, severe breathing issues in adults aged 18 and older. In a recent trial, the results showed that Airsupra reduced the risk of severe asthma flare-ups by 47% versus placebo. In addition, patients using the inhaler had 63% less exposure to systemic corticosteroids during treatment, lowering the risk of long-term side effects such as type 2 diabetes, mental health issues, kidney problems, cataracts, heart disease, pneumonia, and bone fractures. Sharon Barr, Executive Vice-President and Head of BioPharmaceuticals R&D, AstraZeneca PLC (NASDAQ:AZN), made the following statement: 'The exciting results from the BATURA trial, coupled with the findings from MANDALA and DENALI, clearly demonstrate the superiority of Airsupra over albuterol alone across all asthma severities. We hope these comprehensive results accelerate the use of anti-inflammatory rescue therapy as the preferred standard of care, in line with recommendations from the Global Initiative for Asthma.' Airsupra made a favorable contribution to AstraZeneca PLC (NASDAQ:AZN)'s earnings and has the potential to play a more significant role in future profits, particularly in light of the recent trial results. In fiscal year 2024, Airsupra brought in $66 million in revenue. While we acknowledge the potential of AZN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AZN and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
